For patients transplanted in CR1, the 2-year probabilities of leukemia-free survival (LFS) and OS were 57% and 61%, respectively, which were equivalent to the outcomes of other intermediate-risk AML patients.[11] However, these studies did not identify the dynamic evolution of measurable residual disease (MRD, i.e., DEK-NUP214 transcript) before and after allo-HSCT, or the impact of pretransplant MRD status on posttransplant outcomes.[12] In particular, whether DEK-NUP214 transcript positivity before allo-HSCT influences posttransplant clinical outcomes remain unclear. This evidence concerns the gene NUP214 and acute myeloid leukemia.